Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.

[1]  B. Gazzard,et al.  Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers , 2009, Journal of acquired immune deficiency syndromes.

[2]  John D. Davis,et al.  Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment , 2009, Antiviral therapy.

[3]  D. Back,et al.  Maraviroc: Pharmacokinetics and drug Interactions , 2009, Antiviral therapy.

[4]  A. Telenti,et al.  A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  A. D’Avolio,et al.  An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients , 2008, Therapeutic drug monitoring.

[6]  J. Hoogmartens,et al.  Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  M. Peeters,et al.  A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. , 2008, British journal of clinical pharmacology.

[8]  M. Foisy,et al.  Induction Effects of Ritonavir: Implications for Drug Interactions , 2008, The Annals of pharmacotherapy.

[9]  E. Acosta,et al.  A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[10]  J. Poirier,et al.  Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  H. Rosing,et al.  Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  G. Muirhead,et al.  The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. , 2008, British journal of clinical pharmacology.

[13]  G. Muirhead,et al.  Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. , 2008, British journal of clinical pharmacology.

[14]  G. Muirhead,et al.  Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. , 2008, British journal of clinical pharmacology.

[15]  M. Boffito,et al.  A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. , 2008, British journal of clinical pharmacology.

[16]  G. di Perri,et al.  HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[17]  O. Launay,et al.  Quantification of darunavir (TMC114) in human plasma by high-performance liquid chromatography with ultra-violet detection. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[18]  B. Jung,et al.  Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. , 2007, Biomedical chromatography : BMC.

[19]  E. Woolf,et al.  Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[20]  I. Mcintosh,et al.  Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme , 2007, Drug Metabolism and Disposition.

[21]  H. Rosing,et al.  Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liq , 2007, Rapid communications in mass spectrometry : RCM.

[22]  B. Gazzard,et al.  Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures , 2007, AIDS.

[23]  M. Peeters,et al.  Pharmacokinetics of Darunavir/Ritonavir and TMC125 alone and Coadministered in HIV-Negative Volunteers , 2007, Antiviral therapy.

[24]  B. Gazzard,et al.  Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance , 2007, AIDS.

[25]  G. di Perri,et al.  A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[26]  D. Burger,et al.  A Retrospective TDM Database Analysis of Interpatient Variability in the Pharmacokinetics of Lopinavir in HIV-infected Adults , 2006, Therapeutic drug monitoring.

[27]  John T Brooks,et al.  Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study , 2006, Journal of acquired immune deficiency syndromes.

[28]  Tara L. Kieffer,et al.  Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  V. Gaver,et al.  Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers , 2006, Journal of acquired immune deficiency syndromes.

[30]  S. Khoo,et al.  Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[31]  David A. Price,et al.  Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.

[32]  E. Seminari,et al.  Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. , 2005, The Journal of antimicrobial chemotherapy.

[33]  D. Marriott,et al.  Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. , 2005, British journal of clinical pharmacology.

[34]  B. Gazzard,et al.  British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2005) , 2005, HIV medicine.

[35]  C. Ernest,et al.  Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors , 2005, Journal of Pharmacology and Experimental Therapeutics.

[36]  X. Panhard,et al.  Indinavir Plasma Concentration and Adherence Score Are Codeterminant of Early Virologic Response in HIV-Infected Patients of the APROCO Cohort , 2005, Therapeutic drug monitoring.

[37]  H. Rosing,et al.  Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[38]  H. M. Vinkers,et al.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.

[39]  T. Annesley.  Ion suppression in mass spectrometry. , 2003, Clinical chemistry.

[40]  R. Aarnoutse,et al.  Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. , 2003, Journal of acquired immune deficiency syndromes.

[41]  E. Acosta,et al.  Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[42]  R. Aarnoutse,et al.  Treatment Failure of Nelfinavir-Containing Triple Therapy Can Largely Be Explained by Low Nelfinavir Plasma Concentrations , 2003, Therapeutic drug monitoring.

[43]  B. Masquelier,et al.  Human Immunodeficiency Virus Type 1 Genotypic and Pharmacokinetic Determinants of the Virological Response to Lopinavir-Ritonavir-Containing Therapy in Protease Inhibitor-Experienced Patients , 2002, Antimicrobial Agents and Chemotherapy.

[44]  R. Maserati,et al.  Antiretrovirals: Simultaneous Determination of Five Protease Inhibitors and Three Nonnucleoside Transcriptase Inhibitors in Human Plasma by a Rapid High-Performance Liquid Chromatography–Mass Spectrometry Assay , 2001, Therapeutic drug monitoring.

[45]  G. Moyle.  Use of HIV protease inhibitors as pharmacoenhancers. , 2001, The AIDS reader.

[46]  A. Telenti,et al.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients , 2001, AIDS.

[47]  Timothy Olah,et al.  Mechanistic investigation of ionization suppression in electrospray ionization , 2000, Journal of the American Society for Mass Spectrometry.

[48]  T. Olah,et al.  The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. , 1999, Rapid communications in mass spectrometry : RCM.

[49]  A. Dasgupta,et al.  Effect of heating sera under conditions necessary for deactivation of human immunodeficiency virus on commonly monitored therapeutic drugs. , 1994, Therapeutic drug monitoring.

[50]  J. Chermann,et al.  INACTIVATION OF LYMPHADENOPATHY-ASSOCIATED VIRUS BY HEAT, GAMMA RAYS, AND ULTRAVIOLET LIGHT , 1985, The Lancet.

[51]  J O Westgard,et al.  A multi-rule Shewhart chart for quality control in clinical chemistry. , 1981, Clinical chemistry.

[52]  M. Shelton,et al.  Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. , 2006, Clinical pharmacokinetics.

[53]  J. Dieleman,et al.  Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected Population , 2003, Clinical pharmacokinetics.

[54]  J. Beijnen,et al.  Drug Interactions Between Antiretroviral Drugs and Comedicated Agents , 2003, Clinical pharmacokinetics.

[55]  Patrick F. Smith,et al.  Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors , 2001, Clinical pharmacokinetics.